Control of filarial infections: not the beginning of the end, but more research is needed.
Infections with the filarial nematodes affect more than 150 million people mainly in the tropics. The very successful efforts to control filarial infections, however, have to be sustained by new tools that require long-term commitment to research. This review, focusing on reports from 2002 and 2003, highlights recent advances in research on immunology, understanding of pathogenesis and drug development in lymphatic filariasis and onchocerciasis research with potential relevance to the generation of new tools for control. Dramatic improvement has been achieved in the control of lymphatic filariasis and onchocerciasis by vector control and mass treatment with microfilaricidal drugs. Additional tools that could help in regional elimination or, ultimately, eradication of filariasis may arise from the development of new drugs or a vaccine. Research into the immune responses mediating protection or pathology has provided new insights into the pathways that lead to effector function and immunosuppression, such as T regulatory responses, as well as into genetic predispositions from the host's side, and to the identification of vaccine candidates that show protection in animal models. Recognition of the role the Wolbachia endosymbionts may play in activating the innate immune system has altered our understanding of immunopathology of filariasis and adverse reactions to microfilaricidal drugs. Wolbachia spp. have also proven to be suitable targets for the development of a long-term sterilizing or potentially macrofilaricidal drug. This review summarizes recent developments in the control of filariasis, in particular lymphatic filariasis and onchocerciasis, as well as in modern research into the immunity of filariasis and new drug development that could lead to additional tools necessary for sustained success in filariasis control.